Bryce worked with Eli Lilly & Co for over 36 years and was an Executive Committee member and an Officer of the Company. He retired as Executive VP, Eli Lilly and Co & President of Lilly Bio-Medicines in December 2011.
Bryce was responsible for strategy and operations for the Lilly Bio-Medicines Business Unit, which included both clinical development of late-stage products across multiple therapeutic areas and regional sales and marketing operations for the United States, Japan, the European Union, Canada, and Australia / New Zealand. He also was responsible for the Lilly Global Marketing organisation.
Prior to the above role, he held the position of Executive Vice President, Global Marketing and Sales, which encompassed all therapeutic areas and the operational responsibilities for the global pharmaceutical division.
Bryce has had extensive product development leadership roles overseeing post proof-of-concept global development teams for the entire Lilly late-stage pipeline across all therapeutic categories. During his career, he also held multiple operational roles as President of Lilly Japan, Managing director of Australia/New Zealand and General Manager of a Joint Venture in South Korea.
Bryce contributed in leadership positions to the pharmaceutical industry associations internationally. Currently, he is a member of the Deans Council for Indiana University School of Public Policy & Environmental Affairs, Indiana USA and a Board Director of Kazia Therapeutics Ltd. Bryce was born in New Zealand, where he gained his B.Sc. in biochemistry from Massey University. He currently resides in both Chicago and Sydney.
Rosanne has over 20 years of experience in biomedical research, translational medicine, clinical research, regulatory affairs and drug development.
She was a co-founder & Director of Immune System Therapeutics Ltd from 2001 to 2012, where she managed the intellectual property portfolio and was an author on the company's patents. She played a lead role in the isolation of the genes for the lead therapeutic antibody and was involved in taking the antibody from the laboratory through to preclinical and clinical development.
She has experience in the fields of immunology, haematology and molecular biology with particular experience in the development of biologic therapeutics. Rosanne heads the HaemaLogiX team in the development of the chimeric antigen receptor (CAR) clinical program and the clinical development of the antibody pipeline.
Rosanne was awarded a Ph.D. in antibody engineering from the University of Technology, Sydney. She has a Masters of Medical Science from the University of Natal Medical School and a B.Sc. (Hons) in biochemistry from the University of Cape Town in South Africa. She is a graduate of the Australian Institute of Company Directors and is a member of the European Haematology Association, the American Society of Clinical Oncology and the International Myeloma Society. She resides in Sydney.
Dimitra is a Certified Practicing Accountant (CPA), which she obtained after converting her Bachelor of Science Degree (UNSW) through an accounting-bridging course at the University of Technology, Sydney.
As Chief Financial Officer | Company Secretary, Dimitra leads the finance and accounting functions as well as manages the human resource, facilities and corporate IT service areas of HaemaLogiX. Dimitra has 8 years of biotech experience in clinical trial management, clinical manufacturing, R&D forecasting/budgeting and corporate operations.
She was the Company Secretary at Immune System Therapeutics Ltd from 2011 to 2014. She has extensive experience in financial and managerial accounting, risk management and compliance gained in various senior financial roles with Cicada Innovations, CFO Plus, Apostle Financial Management, Absolute Capital Group, Australian Capital Reserve.
Halley has over 20 years experience in all areas of Project Coordination and Management within the Pharmaceutical Industry. Halley has worked within Large Pharmas, CROs and Biotechs across all areas of Clinical Research Management, including Global and Local Trial Management, Monitoring, Training, QC, Manufacturing, Regulatory and Preclinical. Halley was a member of the Immune System Therapeutics team from 2013 -14.
Halley holds a post-graduate Diploma in Drug Development (Medical Science) from the University of New South Wales. In 2008 she received the PharmaTimes International Clinical Researcher of the Year Award.
Rhonda worked in biotech and academic research labs for 12 years before contracting as a medical writer for 10 years. She managed the nonclinical sections of two successful regulatory applications to the FDA in lymphoma before moving on to a dual scientific writer/project manager role in one of the top cancer genomics groups in the world in Vancouver Canada. There she helped researchers secure millions of dollars in funding via grant applications.
After moving to Western Australia in 2006, she contracted to medical communications companies in Australia, the US, the UK and Germany, working on a variety of projects such as attending international conferences and writing conference proceedings, and producing training materials for specialists, GPs, nurses, salespeople and patients in oncology, dermatology, psychiatry and autoimmune diseases.
She also tried her hand at entrepreneurship by co-founding a software development company where she gained experience in business development and marketing. Rhonda has a B.Sc. from the University of Calgary and an editing certificate from Simon Fraser University in Canada.
Mohamad had an academic career that started at the University of Maryland Cancer center 1989-1991. He relocated to the Cleveland Clinic in the summer of 1991 where he created and directed the Multiple Myeloma Research Program, 1996-2006. In January 2006, appointed Director, Malignant Hematology Division and Myeloma Section at the H. Lee Moffitt Cancer Center and the University of South Florida in Tampa, 2006-2008.
Currently, Professor of Medicine and Oncology at the University of South Florida, 2009-Current. During this period, developed multidisciplinary approaches to the understanding and therapy of hematologic malignancies. This included development of phase 1, 2 and 3 compounds through chairing and leading different NCI disease cooperative groups and committees, as well as partnering with pharma. One distinguishing aspect of the CCF program was the utilization of cellular and skeletal therapeutic and supportive approaches to manage multiple myeloma in general as well as end organ damage resulting from the disease.
In August 2008, Dr. Hussein joined Celgene Corporation, where he held different positions in hematology organization, while leading the development of the multiple myeloma franchise strategy in addition to driving the clinical development of Celgene Cell therapy placental program. He retired from Celgene summer 2019 as Corporate Vice President, Global Medical Affairs, Multiple Myeloma and hematology scientific collaborations.
He has 150+ published peer-review manuscripts, book chapters, and editorials. Dr. Hussein is currently serving as an ad hoc reviewer for JCO, Haematologica, BMT Journal and The British Journal of Haematology. He also serves as a reviewer on the LLS and FNIH scientific grant review committees. His interest and contributions have focused on advancing the therapeutic programs in hematologic malignancies at Celgene Corporation. Mohamad's current role focuses on studying disease pathophysiology, developing cellular and immune therapy while creating a fully integrated multiple myeloma therapeutic.